Sotuvning operatsion marjasi: Innate Pharma SA (IPHA)

Innate Pharma S.A (IPHA) kompaniyasining korporativ logotipi

Innate Pharma S.A. (IPHA) uchun xavflar sog'liqni saqlash gigantlari bilan birgalikda amalga oshirilayotgan NK loyihalarining muvaffaqiyatiga bog'liqlik bilan bog'liq. Operatsion marja tendentsiyasi ushbu tebranishlarni aks ettiradi va ushbu ko'rsatkich -1257.00 darajasida turibdi. Barqarorlik noyob antitanachi patentlariga egalik qilish orqali ta'minlanadi, bu esa kompaniyaga sezilarli narx belgilash imkoniyatini beradi. Emitentning daromadlari dunyoning eng yirik korporatsiyalaridan olinadigan daromadli litsenziyalash to'lovlari va oldindan to'lovlarga asoslangan.

IPHA: innate-pharma.com Operatsion foyda normasi 04.07.2022 - 19.11.2026

Innate Pharma S.A. - tahliliy kesimlar va asosiy koʻrsatkichlar (IPHA)

- kompaniyaning birjadagi kapitallashuv ko'rsatkichlari:
Kompaniyaning asosiy tahlili:IPHA, Innate Pharma
Innate Pharma S.A asosiy tovari

Innate Pharma S.A. (IPHA) uchun saraton immunoterapiyasini ishlab chiqish samaradorligi bevosita operatsion marja bilan bog'liqdir. Ushbu ko'rsatkich soliqlar va qarz majburiyatlarining ta'sirini hisobga olmagan holda, operatsion foydaning daromadga nisbati sifatida hisoblanadi. Operatsion daromad marjasini tahlil qilish orqali investor asosiy biznesning haqiqiy daromadliligini aniqlashi mumkin. Biomateriallarni xarid qilishdagi geosiyosiy to'siqlar va logistik inqirozlar vaqtincha ushbu ko'rsatkichni pasaytirishi mumkin. Ushbu indikatorning barqaror o'sishi kompaniyaning tashqi zarbalarga chidamliligini tasdiqlaydi.

Innate Pharma S.A. kimlar bilan raqobatlashadi

Sotuvning operatsion marjasi IBRX|IMCR - Operatsion foyda bo'yicha marjinallik|Sotuvning operatsion marjasi JANX (Janux Pharma)|Operatsion foyda koeffitsiyenti RCUS|Operatsion marja ZYME (Zymeworks)|Operatsion foyda normasi TNGX|iovance.com - Operatsion marja|Sotuvning operatsion rentabelligi Immatics Biotechnologies|Xencor, Inc. (XNCR) - Operatsion rentabellik|Compass Therapeutics - Operatsion foyda normasi|REPL (replimune.com) - Operatsion marja|Operatsion marja Lyell|Operatsion rentabellik pyxisoncology.com (PYXS)|CGEN: Operatsion foyda marjasi|IO Biotech Inc - Sotuvning operatsion marjasi|sutrobio.com (STRO) - Sotuvning operatsion rentabelligi|INKT - Operatsion rentabellik|werewolftx.com (HOWL) - Sotuvning operatsion marjasi|Immix (IMMX) - Operatsion rentabellik|ALXO (ALX Oncology Holdings) - Operatsion rentabellik|Sotuvning operatsion marjasi CUE|PDS Biotechnology Corporation (PDSB) - Operatsion faoliyat rentabelligi|Operatsion rentabellik Sonnet BioTherapeutics Holdings Inc. (SONN)|Operatsion marja MAIA Biotechnology Inc (MAIA)|Operatsion rentabellik Liminatus Pharma LIMN|Operatsion foyda normasi LVTX|NXTC: Sotuvning operatsion marjasi|leaptx.com - Operatsion foyda koeffitsiyenti|INTS: Operatsion marja|Sensei Biotherapeutics Inc - Operatsion foyda normasi|Sotuvning operatsion marjasi TOVX|Operatsion foyda bo'yicha sotuv rentabelligi GRTS (Gritstone bio, Inc.)|Sotuvning operatsion marjasi KA (kinetabio.com)|NEXI - Sotuvning operatsion rentabelligi|Turnstone Biologics - Sotuvning operatsion marjasi|Operatsion faoliyat rentabelligi Vaccinex Inc. (VCNX)|harpoontx.com - Operatsion marja